Cargando…

High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial

PURPOSE: Patients with high bleeding risk (HBR) who undergo percutaneous coronary intervention also have an increased risk of ischemic events and represent an overall high-risk population. The coating of durable polymer drug-eluting stents (DP-DES) may induce inflammation and delay arterial healing,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zocca, Paolo, Kok, Marlies M., van der Heijden, Liefke C., Danse, Peter W., Schotborgh, Carl E., Scholte, Martijn, Hartmann, Marc, Linssen, Gerard C. M., Doggen, Carine J. M., von Birgelen, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267643/
https://www.ncbi.nlm.nih.gov/pubmed/30143879
http://dx.doi.org/10.1007/s10557-018-6823-9
_version_ 1783376122054967296
author Zocca, Paolo
Kok, Marlies M.
van der Heijden, Liefke C.
Danse, Peter W.
Schotborgh, Carl E.
Scholte, Martijn
Hartmann, Marc
Linssen, Gerard C. M.
Doggen, Carine J. M.
von Birgelen, Clemens
author_facet Zocca, Paolo
Kok, Marlies M.
van der Heijden, Liefke C.
Danse, Peter W.
Schotborgh, Carl E.
Scholte, Martijn
Hartmann, Marc
Linssen, Gerard C. M.
Doggen, Carine J. M.
von Birgelen, Clemens
author_sort Zocca, Paolo
collection PubMed
description PURPOSE: Patients with high bleeding risk (HBR) who undergo percutaneous coronary intervention also have an increased risk of ischemic events and represent an overall high-risk population. The coating of durable polymer drug-eluting stents (DP-DES) may induce inflammation and delay arterial healing, which might be reduced by novel biodegradable polymer DES (BP-DES). We aimed to evaluate the safety and efficacy of treating HBR patients with very thin-strut BP-DES versus thin-strut DP-DES. METHODS: Participants in BIO-RESORT (NCT01674803), an investigator-initiated multicenter, randomized all-comers trial, were treated with very thin-strut BP-DES (Synergy or Orsiro) or thin-strut DP-DES (Resolute Integrity). For the present analysis, patients were classified following HBR criteria based on previous trials. The primary endpoint was target vessel failure: a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization at 1 year. RESULTS: Of all 3514 patients, 1009 (28.7%) had HBR. HBR patients were older (p < 0.001) and had more co-morbidities than non-HBR patients (p < 0.001). At 1-year follow-up, HBR patients had significantly higher rates of target vessel failure (6.7 vs. 4.2%, p = 0.003), cardiac death (1.9 vs. 0.4%, p < 0.001), and major bleeding (3.3 vs. 1.5%, p = 0.001). Of all 1009 HBR patients, 673 (66.7%) received BP-DES and 336 (33.3%) had DP-DES. The primary endpoint was met by 43/673 (6.5%) patients treated with BP-DES and 24/336 (7.3%) treated with DP-DES (HR 0.88 [95%CI 0.54–1.46], p = 0.63). There were no significant between-group differences in the most global patient-oriented clinical endpoint (9.7 vs. 10.5%, HR 0.92 [95%CI 0.61–1.39], p = 0.69) and other secondary endpoints. CONCLUSIONS: At 1-year follow-up, very thin-strut BP-DES showed similar safety and efficacy for treating HBR patients as thin-strut DP-DES. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10557-018-6823-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6267643
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-62676432018-12-11 High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial Zocca, Paolo Kok, Marlies M. van der Heijden, Liefke C. Danse, Peter W. Schotborgh, Carl E. Scholte, Martijn Hartmann, Marc Linssen, Gerard C. M. Doggen, Carine J. M. von Birgelen, Clemens Cardiovasc Drugs Ther Original Article PURPOSE: Patients with high bleeding risk (HBR) who undergo percutaneous coronary intervention also have an increased risk of ischemic events and represent an overall high-risk population. The coating of durable polymer drug-eluting stents (DP-DES) may induce inflammation and delay arterial healing, which might be reduced by novel biodegradable polymer DES (BP-DES). We aimed to evaluate the safety and efficacy of treating HBR patients with very thin-strut BP-DES versus thin-strut DP-DES. METHODS: Participants in BIO-RESORT (NCT01674803), an investigator-initiated multicenter, randomized all-comers trial, were treated with very thin-strut BP-DES (Synergy or Orsiro) or thin-strut DP-DES (Resolute Integrity). For the present analysis, patients were classified following HBR criteria based on previous trials. The primary endpoint was target vessel failure: a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization at 1 year. RESULTS: Of all 3514 patients, 1009 (28.7%) had HBR. HBR patients were older (p < 0.001) and had more co-morbidities than non-HBR patients (p < 0.001). At 1-year follow-up, HBR patients had significantly higher rates of target vessel failure (6.7 vs. 4.2%, p = 0.003), cardiac death (1.9 vs. 0.4%, p < 0.001), and major bleeding (3.3 vs. 1.5%, p = 0.001). Of all 1009 HBR patients, 673 (66.7%) received BP-DES and 336 (33.3%) had DP-DES. The primary endpoint was met by 43/673 (6.5%) patients treated with BP-DES and 24/336 (7.3%) treated with DP-DES (HR 0.88 [95%CI 0.54–1.46], p = 0.63). There were no significant between-group differences in the most global patient-oriented clinical endpoint (9.7 vs. 10.5%, HR 0.92 [95%CI 0.61–1.39], p = 0.69) and other secondary endpoints. CONCLUSIONS: At 1-year follow-up, very thin-strut BP-DES showed similar safety and efficacy for treating HBR patients as thin-strut DP-DES. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10557-018-6823-9) contains supplementary material, which is available to authorized users. Springer US 2018-08-24 2018 /pmc/articles/PMC6267643/ /pubmed/30143879 http://dx.doi.org/10.1007/s10557-018-6823-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Zocca, Paolo
Kok, Marlies M.
van der Heijden, Liefke C.
Danse, Peter W.
Schotborgh, Carl E.
Scholte, Martijn
Hartmann, Marc
Linssen, Gerard C. M.
Doggen, Carine J. M.
von Birgelen, Clemens
High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial
title High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial
title_full High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial
title_fullStr High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial
title_full_unstemmed High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial
title_short High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial
title_sort high bleeding risk patients treated with very thin-strut biodegradable polymer or thin-strut durable polymer drug-eluting stents in the bio-resort trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267643/
https://www.ncbi.nlm.nih.gov/pubmed/30143879
http://dx.doi.org/10.1007/s10557-018-6823-9
work_keys_str_mv AT zoccapaolo highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT kokmarliesm highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT vanderheijdenliefkec highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT dansepeterw highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT schotborghcarle highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT scholtemartijn highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT hartmannmarc highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT linssengerardcm highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT doggencarinejm highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial
AT vonbirgelenclemens highbleedingriskpatientstreatedwithverythinstrutbiodegradablepolymerorthinstrutdurablepolymerdrugelutingstentsinthebioresorttrial